COMP <GO>
VRTX vs LLY // EV/EBITDA & P/E VALUATION
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: VRTX 6
— LLY 9
▲ EV/EBITDA & P/E VALUATION LEADER: VRTX
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
valuation
29.6x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 83.64% | +2.56 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 32.36% | -12.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 29.6x | 36.4x | -6.82 | VRTX | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 2.30% | +0.03 | VRTX | /fcf-yield <GO> |
| Operating Margin | 34.80% | 40.21% | -5.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 32.90% | 31.90% | +1.00 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 45.51% | -36.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 9.29 | +4.57 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 77.9 | -10.23 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.51 | +0.51 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 26.3x | +5.95 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $1.33T | -$1.20T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | LLY REV | VRTX GROSS % | LLY GROSS % | VRTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $65.18B | 86.2% | 83.0% | $3.19B | $16.81B |
| FY 2024 | $11.02B | $45.04B | 86.1% | 81.3% | -$790.3M | $8.82B |
| FY 2023 | $9.87B | $34.12B | 44.0% | 79.3% | $3.09B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
LLY // BETA 0.51